Supernus [SUPN] vs Zoetis [ZTS] Detailed Stock Comparison

Supernus Pharmaceuticals Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Supernus Pharmaceuticals Inc. wins in 7 metrics, Zoetis Inc. wins in 13 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Supernus Pharmaceuticals Inc. Zoetis Inc. Better
P/E Ratio (TTM) 40.66 19.58 Zoetis Inc.
Price-to-Book Ratio 2.66 15.04 Supernus Pharmaceuticals Inc.
Debt-to-Equity Ratio 3.86 279.59 Supernus Pharmaceuticals Inc.
PEG Ratio -0.33 2.81 Zoetis Inc.
EV/EBITDA 22.87 13.96 Zoetis Inc.
Profit Margin (TTM) -5.36% 28.24% Zoetis Inc.
Operating Margin (TTM) 5.57% 34.69% Zoetis Inc.
EBITDA Margin (TTM) 5.57% 34.69% Zoetis Inc.
Return on Equity -3.68% 65.99% Zoetis Inc.
Return on Assets (TTM) 1.14% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $45.99M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 45.68% -53.93% Supernus Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 3.93 5.26 Supernus Pharmaceuticals Inc.
Enterprise Value $2.68B $56.75B Zoetis Inc.
EV/Revenue Ratio 3.73 6.00 Supernus Pharmaceuticals Inc.
Gross Profit Margin (TTM) 89.13% 70.17% Supernus Pharmaceuticals Inc.
Revenue per Share (TTM) $13 $21 Zoetis Inc.
Earnings per Share (Diluted) $-0.68 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.73 0.97 Supernus Pharmaceuticals Inc.
Short % of Float 11.09% 4.06% Zoetis Inc.

Supernus Pharmaceuticals Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

SUPN
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Supernus Pharmaceuticals Inc.-0.06%-7.75%-9.38%-20.00%-0.11%-10.92%
Zoetis Inc.1.51%-4.46%-31.75%-39.76%-38.95%-38.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Supernus Pharmaceuticals Inc.45.68%37.73%54.55%136.46%673.53%673.53%
Zoetis Inc.-53.93%-54.80%-55.66%62.09%150.53%150.53%

Performance & Financial Health Analysis: Supernus Pharmaceuticals Inc. vs Zoetis Inc.

MetricSUPNZTS
Market Information
Market Cap i$2.83B$49.75B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i492,6942,727,710
90 Day Avg. Volume i568,6013,835,940
Last Close$44.05$167.10
52 Week Range$30.83 - $59.68$139.70 - $200.33
% from 52W High-26.20%-16.59%
All-Time High$61.25 (Jun 25, 2018)$249.27 (Dec 27, 2021)
% from All-Time High-28.08%-32.96%
Growth Metrics
Quarterly Revenue Growth0.22%0.03%
Quarterly Earnings Growth0.21%0.04%
Financial Health
Profit Margin (TTM) i-0.05%0.28%
Operating Margin (TTM) i0.06%0.35%
Return on Equity (TTM) i-0.04%0.66%
Debt to Equity (MRQ) i3.86279.59
Cash & Liquidity
Book Value per Share (MRQ)$18.48$7.84
Cash per Share (MRQ)$5.36$5.48
Operating Cash Flow (TTM) i$47.33M$2.90B
Levered Free Cash Flow (TTM) i$101.29M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Supernus Pharmaceuticals Inc. vs Zoetis Inc.

MetricSUPN (Apr 22, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i40.6619.58
Forward P/E i11.6415.61
PEG Ratio i-0.332.81
Price to Sales (TTM) i3.935.26
Price to Book (MRQ) i2.6615.04
Market Capitalization
Market Capitalization i$2.83B$49.75B
Enterprise Value i$2.68B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i3.736.00
Enterprise to EBITDA i22.8713.96
Risk & Other Metrics
Beta i0.730.97
Book Value per Share (MRQ) i$18.48$7.84

Financial Statements Comparison: Supernus Pharmaceuticals Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSUPN (2025)ZTS (2025)
Revenue/Sales i718.95M9.47B
Cost of Goods Sold i74.56M2.67B
COGS % of Revenue i10.4%28.2%
Gross Profit i644.39M6.80B
Gross Margin i89.6%71.8%
Research & Development i106.24M698.00M
Operating Income (EBIT) i-36.86M3.60B
Operating Margin i-5.1%38.0%
EBITDA i67.95M4.17B
EBITDA Margin i9.5%44.1%
Pre-Tax Income i-49.03M3.36B
Pre-Tax Income % of Revenue i-6.8%35.5%
Income Tax i-10.48M687.00M
Income Tax % of Revenue i-1.5%7.3%
Net Income (Profit) i-38.55M2.67B
Profit Margin i-5.4%28.2%

Balance Sheet & Liquidity Metrics

MetricSUPN (2025)ZTS (2025)
Cash & Equivalents i128.45M2.31B
Total Current Assets i644.18M6.77B
Total Current Assets % of Revenue i89.6%71.5%
Total Current Liabilities i338.17M2.24B
Total Current Liabilities % of Revenue i47.0%23.6%
Long-Term Debt i30.37M9.24B
Long-Term Debt % of Revenue i4.2%97.6%
Total Shareholders Equity i1.06B3.33B
Retained Earnings i517.88M13.74B
Retained Earnings % of Revenue i72.0%145.2%
Property, Plant & Equipment i0288.00M

Cash Flow Statement Comparison

MetricSUPN (2025)ZTS (2025)
Operating Cash Flow i67.28M2.78B
Operating Cash Flow % of Revenue i9.4%29.3%
Capital Expenditures i-1.34MN/A
Free Cash Flow i45.99M2.28B
FCF Margin i6.4%24.1%
Debt Repayment i0-1.35B
Common Stock Repurchase iN/A-3.24B

Short Interest & Institutional Ownership Analysis

MetricSUPNZTS
Shares Short i4.53M15.12M
Short Ratio i7.263.60
Short % of Float i11.09%4.06%
Shares Outstanding i57.46M424.93M
Float Shares i51.79M421.29M
% Held by Insiders i4.34%0.15%
% Held by Institutions i105.00%101.50%
% Held by Public i-9.34%-1.65%

Dividend Analysis & Yield Comparison: Supernus Pharmaceuticals Inc. vs Zoetis Inc.

MetricSUPNZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026